ArriVent BioPharma, Inc. Common Stock (AVBP) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 6 Buy.
The consensus price target is $44.00 (low: $43.00, high: $45.00), representing an upside of 59.2% from the current price $27.64.
Analysts estimate Earnings Per Share (EPS) of $-2.58 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.56 vs est $-2.58 (beat +0.8%). 2025: actual $-4.32 vs est $-4.41 (beat +2%). Analyst accuracy: 99%.
AVBP Stock — 12-Month Price Forecast
$44.00
▲ +59.19% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for ArriVent BioPharma, Inc. Common Stock, the average price target is $44.00, with a high forecast of $45.00, and a low forecast of $43.00.
The average price target represents a +59.19% change from the last price of $27.64.
Highest Price Target
$45.00
Average Price Target
$44.00
Lowest Price Target
$43.00
AVBP Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to ArriVent BioPharma, Inc. Common Stock in the past 3 months
EPS Estimates — AVBP
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.56
vs Est –$2.58
▲ 0.8% off
2025
Actual –$4.32
vs Est –$4.41
▲ 2.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — AVBP
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
